The Latest Research to Address Symptoms of Alzheimer's Disease
Monday, March 17, 2025
12:00 PM - 1:00 PM EDT
24/7 Helpline: (800) 272-3900
There are many different types of clinical research studies being conducted by researchers at Johns Hopkins. Clinical research studies are designed to improve our understanding of healthy aging and diseases that cause memory loss and dementia, find improved treatments for these diseases, find ways of reducing risk for memory disorders, and to test interventions designed to improve the support and care received by persons with dementia and their caregivers. This webinar will provide an overview of three innovative approaches to address Alzheimer’s disease and its symptoms.
Additional Information
Featured speakers and the studies to be presented:
Dr. Esther Oh, MD, PhD, Division of Geriatric Medicine and Gerontology, Department of Medicine, Johns Hopkins University School of Medicine
HEARS-NPS Hearing health Equity through Accessible Research and Solutions- Neuropsychiatric Symptoms: Hearing loss is very common in older adults, especially in those who have dementia. Hearing loss can contribute to poor comprehension and miscommunication that can often lead to frustration in both the patient and the caregiver. The goal of this study is to improve behavioral symptoms associated with dementia by providing hearing assistive device and education in improving communication.
Dr. Barry Greenberg, PhD, Department of Neurology, Johns Hopkins University School of Medicine
RESTStudy: Persons with very early stages of Alzheimer's disease, known as Mild Cognitive Impairment, often have problems with sleep, and there is evidence that poor sleep may contribute to cognitive decline. Trazodone is an FDA-approved medication widely used off-label to improve sleep. The goal of this study is to compare the effect of 1 month trazodone vs. placebo in 100 older adults with MCI and sleep complaints, to determine trazodone improves sleep and memory function.
Dr. Arnold Bakker, PhD, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine
The HOPE4MCI study is an 18-month clinical trial assessing the efficacy of AGB101 for the treatment of Mild Cognitive Impairment due to Alzheimer’s disease. AGB101 is a once-a-day low dose formulation of levetiracetam, an existing medication that has been used in much higher doses to treat seizures disorders. Extensive prior clinical research suggests that this medication is beneficial for people with memory impairments and may slow neurodegeneration associated with Alzheimer's disease.
Information
- Delivery Method: Phone/Webinar
- Date: Monday, March 17, 2025
- Time: 12:00 PM - 1:00 PM EDT
- Audience: Caregivers
- Languages: English
Contact
-
Primary Contact:
- 24/7 Helpline: (800) 272-3900
Register
-
Registration Info:
- Registration Opens: Thursday, August 1, 2024
- Deadline Date: Monday, March 17, 2025
- Type: Registration Preferred (Not Required)
-
Payment Informations:
- Event Fee: Free
Donations accepted and appreciated.
Information
Featured speakers and the studies to be presented:
Dr. Esther Oh, MD, PhD, Division of Geriatric Medicine and Gerontology, Department of Medicine, Johns Hopkins University School of Medicine
HEARS-NPS Hearing health Equity through Accessible Research and Solutions- Neuropsychiatric Symptoms: Hearing loss is very common in older adults, especially in those who have dementia. Hearing loss can contribute to poor comprehension and miscommunication that can often lead to frustration in both the patient and the caregiver. The goal of this study is to improve behavioral symptoms associated with dementia by providing hearing assistive device and education in improving communication.
Dr. Barry Greenberg, PhD, Department of Neurology, Johns Hopkins University School of Medicine
RESTStudy: Persons with very early stages of Alzheimer's disease, known as Mild Cognitive Impairment, often have problems with sleep, and there is evidence that poor sleep may contribute to cognitive decline. Trazodone is an FDA-approved medication widely used off-label to improve sleep. The goal of this study is to compare the effect of 1 month trazodone vs. placebo in 100 older adults with MCI and sleep complaints, to determine trazodone improves sleep and memory function.
Dr. Arnold Bakker, PhD, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine
The HOPE4MCI study is an 18-month clinical trial assessing the efficacy of AGB101 for the treatment of Mild Cognitive Impairment due to Alzheimer’s disease. AGB101 is a once-a-day low dose formulation of levetiracetam, an existing medication that has been used in much higher doses to treat seizures disorders. Extensive prior clinical research suggests that this medication is beneficial for people with memory impairments and may slow neurodegeneration associated with Alzheimer's disease.
- Delivery Method: Phone/Webinar
- Date: Monday, March 17, 2025
- Time: 12:00 PM - 1:00 PM EDT
- Time Zone: EDT
- Audience: Caregivers
- Languages: English
Contact
-
Primary Contact:
- 24/7 Helpline: (800) 272-3900
Register
-
Registration Info:
- Registration Opens: Thursday, August 1, 2024
- Deadline Date: Monday, March 17, 2025
- Type: Registration Preferred (Not Required)
-
Payment Informations:
- Event Fee: Free
Donations accepted and appreciated.
Powered by
